34 results about "MI - Myocardial infarction" patented technology

Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and / or PAOD.

The invention relates to substituted triazine phenyl urea derivatives and application of the derivatives used as protein kinases, especially as Raf-1 inhibitors. The compounds provided by the invention can be used for treating various disorders and diseases, especially the protein-kinase-related diseases such as cancers, miocardial infarction, cerebral thrombosis, anaemia, hepatitis C (HCV) and other diseases.

The invention discloses a rapid immunofluorescence quantitative detection kit for multi-indicator detection of myocardial infarction. The rapid immunofluorescence quantitative detection kit for multi-indicator detection of myocardial infarction includes a nitrocellulose membrane, and one end of the nitrocellulose membrane is provided with The sample pad is provided with a water-absorbing pad at the other end of the nitrocellulose membrane, and the area between the water-absorbing pad and the sample pad of the nitrocellulose membrane is respectively coated with anti-troponin I, myoglobin, CK- MB antibody and internal quality control antibody. The invention utilizes the fluorescence characteristics of fluorescent particles with different diameters, combines chemical cross-linking labeling technology and immunochromatography technology, and realizes immunofluorescence quantitative detection on the basis of optimizing each component of the test strip. Compared with the conventional colloidal gold immunochromatography method, the present invention has the advantages of good labeling stability, low non-specificity, high sensitivity, small cross-interference and accurate quantification.

The invention belongs to the medication technical field, which discloses the medicine and the preparation method for treating the coronary heart disease and miocardial infarction. The medicine is mainly prepared from ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali and Chinese angelica, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig and liquorice, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig, liquorice, danshen root, red peony root, radix notoginseng and safflower, according to certain ratios of weights. The invention can be made to any type of medicament that can be accepted by the clinic or pharmacology, which is the good quality oral preparation. The medicine has effects of Qi-replenishing, Yin-nourishing and pulse-invigorating and blood circulation activating to dissipate blood stasis and lipid lowing, which can be used to curing the chest distress, hard breathe, heart-throb, angina and arrhythmia caused by coronary heart disease and miocardial infarction, the recovery period of the cerebral thrombosis and the sequelae of the cerebral thrombosis, the effects are obvious.

The invention relates to a ginseng stem leaf total sapogenin oral pharmaceutical preparation as well as a preparation method and an application thereof, belonging to the field of traditional Chinese medicines. Total aglycone extracted from ginseng stem leaf is hydrolyzed to obtain ginseng stem leaf total sapogenin, and the ginseng stem leaf total sapogenin is made into an efficient preparation by matching with a special auxiliary material, thereby the bioavailability of the ginseng stem leaf total sapogenin can be greatly improved. The preparation has obvious curative effect in the aspect of curing diseases such as coronary heart disease, stenocardia, miocardial infarction, hepatitis, tumour, pulmonary heart disease, high blood pressure, and the like or the aspect of preventing depressive illness and senile-resistant.

The invention discloses a potassium magnesium aspartate sterile powder injection and a method for preparing the same. The method is as follows: polyaspartate, magnesium oxide and potassium Hydroxide are prepared into a solution according to a certain method to obtain a liquid medicine, the liquid medicine is subject to reduced-pressure vacuum drying, solvent crystallization or spray drying, and is prepared into sterile packaged products for injection. The potassium magnesium aspartate sterile powder injection of the invention has the advantages of rapid redissolution, excellent stability, simple process, low production cost, suitability for industrial production, etc. the potassium magnesium aspartate sterile powder injection is mainly used for supplementing electrolyte, and can also be used for the treatment of hypokalemia and arrhythmia (mainly ventricular arrhythmia) caused by digitalism, and for the adjuvant treatment of myocarditis sequela, congestive heart failure, and miocardial infarction.

An immunofluorescence test strip component for quickly and quantitatively detecting myocardial creatine kinase isozyme comprises a test strip and specific antibodies with platinum-porphyrin marks, the specific antibodies are used with the test strip and are independently packed, the test strip comprises a bottom liner, an absorbent pad, an envelope analysis membrane and a sample pad, the absorbent pad, the envelope analysis membrane and the sample pad are sequentially jointed on the bottom liner, a detection line and a quality control line are disposed on the envelope analysis membrane, the specific antibody enveloped by the detection line is a monoclonal antibody resisting the myocardial creatine kinase isozyme, the specific antibody enveloped by the quality control line is a rabbit IgG (intravenous gamma globulin) antibody, and accordingly the specific bodies with the platinum-porphyrin marks are the monoclonal antibody resisting the myocardial creatine kinase isozyme and the antibody resisting the rabbit IgG. The invention further discloses a preparation method for the detection test strip component, a detection card comprising the test strip component and a preparation method of the detection card. The detection test strip component can simply, quickly and sensibly detect the level of the myocardial creatine kinase isozyme in a human body, and is used for diagnosing acute myocardial infarction.

The invention discloses a conductive micro-needle patch integrated with myocardial cells derived from induced pluripotent stem cells and a preparation method for the conductive micro-needle patch andapplication of the conductive micro-needle patch. The patch consists of a micro-needle array layer, carbon nanotube layers and a hydrogel scaffold layer which are sequentially superimposed, wherein the carbon nanotube layers are integrated with the myocardial cells derived from the induced pluripotent stem cells and are arranged in parallel. A hydrogel prepolymer solution fills pores of a templateand is solidified to form the micro-needle array layer, then the carbon nanotubes layers arranged in parallel are deposited, and finally, the hydrogel prepolymer solution is filled again and is solidified, and the conductive micro-needle patch is obtained after the template is stripped; and the conductive micro-needle patch is used for subsequent differentiation culture of the induced pluripotentstem cells. The patch provided by the invention has a simple preparation method, is not restricted by cell sources, and is expected to become an effective therapeutic carrier for treatment of myocardial infarction.

The invention discloses an asymmetric syntheses method of (-)-sodium danshensu and an application thereof, which belongs to the medicine chemical field. The method comprises the following steps: A)taking levodopa shown in a formula I as a raw material, and performing a hydroxyl acetylation to obtain S-3-(3,4-acetylphenyl)-2-alanine hydrochloride; B)performing a diazotization reaction on S-3-(3,4-acetylphenyl)-2-alanine hydrochloride obtained in the step A) to obtain S-3-(3,4-acetylphenyl)-2-hydracrylicacid in a formula III; C)performing hydrolysis on the S-3-(3,4-acetylphenyl)-2-hydracrylicacid in the step B to obtain S-3-(3,4-dihydroxy phenyl)-2-hydracrylicacid shown in a formula IV; and D)dropping a sodium bicarbonate saturated solution in the S-3-(3,4-dihydroxy phenyl)-2-hydracrylicacid to react to obtain sodium salt (-)-sodium danshensu shown in a formula V. The method has the advantages of easily available raw material and simple operation, and the (-)-sodium danshensu has good effect for treating myocardial ischemia and myocardial infarction.

The invention belongs to the technical field of medicine and discloses a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition is prepared by ginsenoside and carithamine as main ingredients and can be prepared into pharmaceutically or clinically acceptable dosage forms. The pharmaceutical composition has functions of expanding blood vessels of brain, reducing cerebral vascular resistance, increasing cerebral blood flow, obviously minimizing infarct area of brain tissues, obviously lightening behavior disorders caused by brain tissue necrosis, and the like, and can be used for preparing medicaments for treating diseases such as cerebral circulation insufficiency, cerebral thrombosis, cerebral embolism, brain blood vessels spasm, brain insufficiency, senile dementia, Parkinsonism, cerebral apoplexy, hypertension, hyperlipemia, arteriosclerosis, coronary heart disease, angina pectoris, miocardial infarction, etc.

The invention discloses a medicine used for curing the diseases such as coronary heart disease, angina, miocardial infarction, retinal artery or vein occlusion and sudden deafness, etc. and a preparation method thereof. The invention aims at making up the deficiency of the prior art and provides a puerarin sustained-release pill preparation. In the constituents adopted by the prior art, the puerarin sustained-release pill related by the invention utilizes hydrophilic framework material and hydrophobic framework material as stroma and is added with stabilizing agent vitamin C, so as to effectively overcome the defects of the prior art and ensure that the medicaments do not have apparent change relating to the material contents within the valid storing period; furthermore, the puerarin sustained-release pill has the advantages of enough medicine release, controllable medicine releasing time, few times needed by the patient to take the medicine, long time for taking effect and high bioavailability, and is suitable for clinic and family.

The invention discloses a miocardial infarction monitor which consists of a sensing amplifying shaping circuit, a frequency / voltage conversion circuit and an audio oscillation alarming circuit. The sensing amplifying shaping circuit comprises a piezoceramics, two inverters, two resistances and an LED; the frequency / voltage conversion circuit comprises a 555 time base integrated circuit which forms a monostabillity delay circuit together with a resistance, a capacitance and a trigger dynatron. The audio oscillation alarming circuit and an oscillation clearance are controlled by the PWL or the pulse of the output end of the 555 time base integrated circuit. When a cardiac rate is faster than 48, the miocardial infarction monitor does not alarm, but the LED and the cardiac rate twinkle and display synchronously; when the cardiac rate is slower than 48, the miocardial infarction monitor controls the clearance for alarming; the clearance rate and the cardiac rate are synchronous; when the cardiac rate suddenly stops, the miocardial infarction monitor ceaselessly and continuously alarms.

The invention relates to a cotinus coggygria scop compound preparation, which is prepared from cotinus coggygria scop, rhizoma corydalis and hawkthorn in proportion, wherein the dosage of the cotinus coggygria scop is equal to that of the hawkthorn, and the dosage of the rhizoma corydalis is not more than 2 / 3 of that of the cotinus coggygria scop or the hawkthorn. The cotinus coggygria scop compound preparation can be used as an anticoagulant and antithrombotic drug, an abirritation drug, a drug for activating blood circulation to dissipate blood stasis and reducing the whole blood viscosity, a drug for improving the organism anti-hypoxia effect, and a drug for treating coronary heart disease or coronarism or miocardial infarction. The cotinus coggygria scop compound preparation not only improves the curative effect of the cotinus coggygria scop, but also reduces the dosage, and is used for easing pain and treating cardiovascular and cerebrovascular disease. Comparative experiments prove that the compound preparation has equivalent anticoagulant activity and abirritation as aspirin, and has the function of organism hypoxia resistance.

The invention discloses N, -2 substituted phenyl derivates of 4-methoxyl-1, 3-phenylene acyl diamine, and the usage thereof. A compound provided by the invention has the activity for inhibiting the collection of blood platelet, and is applicable for the diseases such as miocardial infarction, cerebrovascular disorder, pulmonary embolism, atherosclerosis, and so on. Moreover, the compound also has the activities of antifebrile, pain killing, inflammation resisting, and so on.

The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material.

The invention relates to novel application of structure modified products of salvianolic acid B in pharmacy. The structure modified products of the salvianolic acid B can obviously inhibit the rise of CK and LDH in blood serum, obviously reduce MDA level and improve SOD activity, has effects of resisting oxidation and removing oxygen radical, can improve the condition of myocardial ischemia to obviously relieve the illness state of miocardial infarction, can obviously prolong the time for forming thrombus, and can be applied in preparing medicaments for resisting the myocardial ischemia, medicaments for protecting myocardial ischemia-reperfusion cardiac microvascular endothelial cells, medicaments for resisting cerebral ischemia, medicaments for resisting atherosclerosis, medicaments for resisting the thrombus, anti-ageing medicaments, antitumor medicaments, and medicaments for resisting liver injury and liver fibrosis. The novel application has the advantage that: the application range of the structure modified products of the salvianolic acid B in pharmacy is determined, so that the preparation of the novel medicaments of which the pharmacological activity and bioavailability are higher than those of the salvianolic acid B is possible.

The medicine composition for treating coronary heart disease and angina pectoris is prepared with ginseng stem and leaf total saponin, white peony root and curcuma root. Its red peony root component is extracted via water decoction and alcohol deposition. The medicine composition may be prepared into capsule, tablet, granule, oral liquid or other preparation form. It is suitable for treating coronary heart disease with insufficient blood supply, miocardial infarction, arrhythmia, cardiac functional insufficiency, etc.

The present invention relates to the field of myocardial infraction (MI). It more specifically relates to an agent stimulating, either directly or indirectly, the 5-hydroxytryptamine 1B receptor, and to a composition comprising said agent, for use in the treatment of a patient having a myocardial infraction (MI). The invention further encompasses therapeutic and screening methods.

The invention discloses a preparation method of a traditional Chinese medicine for treating myocardial infarction. The traditional Chinese medicine is characterized by being prepared from the following raw materials by weight: 8 grams of raw cattail pollen, 8 grams of red sage root, 8 grams of longstamen onion bulb, 8 grams of snakegourd fruit, 8 grams of cassia twig, 8 grams of pinellia ternate, 8 grams of peach seed, 8 grams of safflower, 8 grams of flying squirrel feces, 8 grams of pseudo-ginseng, 3 grams of amber, and 500 grams of water. The preparation and application method comprises the following steps: soaking the raw cattail pollen, red sage root, longstamen onion bulb, snakegourd fruit, cassia twig, pinellia ternate, peach seed, safflower, flying squirrel feces, pseudo-ginseng, and amber in water for 30 minutes, placing the raw materials into a container such as a marmite, a ceramic pot or a crock, decocting for two times, and finally emerging the two decoctions, wherein the total volume of the emerged decoction is 150 to 200 mL; drinking the decoction with a warm temperature, drinking one decoction for a day, and drinking the decoction before breakfast and dinner. People who have the difficulty in taking the decoction can drink the decoction for several times, and a treatment comprises 5 decoctions.

The present invention relates to traditional Chinese medicine, in particular to a black fungus and purple perilla seed composite capsule having effects of lowering blood fat, preventing thrombosis, myocardial infarction and cerebral infarction, improving organism immune function and preventing against aging. The black fungus and purple perilla seed composite capsule is characterized by consisting of the following raw materials (parts by weight): 3.6-5.1 parts of black fungus, 4-5 parts of salisburia adiantifolia, 2.5-4.0 parts of purple perilla seeds, 1.5-3.0 parts of radix puerariae, 2.5-4.0 parts of rhizoma polygonati and 2.5-4.0 parts of cordate houttuynia. The composite capsule is prepared by the following steps: drying the black fungus and crushing the dried black fungus into black fungus powder which can sift through 100 mesh sieves for next steps, then washing and cleaning the salisburia adiantifolia, purple perilla seeds, radix puerariae, rhizoma polygonati and cordate houttuynia, adding water to boiling twice with two hours for each time, merging the boiled liquids, filtrating, concentrating the filtrate into a thick paste and drying at a temperature of 80 DEG C, spraying the dried paste into a powder and sifting through 100 mesh sieves, then mixing the black fungus powder and the above traditional Chinese medicine extract powder evenly, and packaging the mixed powders into capsules. The advantages of the silver fungus powder composite capsule are that the composite capsule has simple technology and convenient operation, is suitable for industrial production, has effects of lowering blood fat, preventing thrombosis, myocardial infarction and cerebral infarction, improving organism immune function and preventing against aging, and has a markedly effective rate of more than 96%, an effective rate of more than 89% and a cure rate of 83%.

The invention relates to the field of compound application, and discloses an indolinone compound and application thereof in myocardial injury. As a calcium / calmodulin kinase II inhibitor, the indolinone compound and the pharmaceutical salt thereof have an improvement effect on myocardial cell death, and can effectively reduce myocardial infarction areas of myocardial ischemia reperfusion mice, myocardial infarction mice and heart failure mice, repair myocardial indexes and relieve cardiac dysfunction. Inhibitors and drugs prepared from the indolinone compound and the pharmaceutical salt thereof have no toxic or side effect and have a remarkable treatment effect.

The present invention relates to vesicles derived from Coprococcus sp. bacteria, and a use thereof. The present inventors experimentally confirmed that: compared to those of a normal person, the vesicles are significantly reduced in clinical samples from patients with breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation; and when the vesiclesisolated from a strain are administered, the secretion of inflammatory mediators by pathogenic vesicles, such as vesicles derived from Escherichia coli, is notably inhibited. Thus, the vesicles derived from Coprococcus sp. bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy or atrial fibrillation; and a composition for preventing, treating or improving gastritis, stomach cancer, colitis, colorectal cancer, breast cancer, ovarian cancer,bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation or inflammatory diseases.

The invention belongs to the medication technical field, which discloses the medicine and the preparation method for treating the coronary heart disease and miocardial infarction. The medicine is mainly prepared from ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali and Chinese angelica, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig and liquorice, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig, liquorice, danshen root, red peony root, radix notoginseng and safflower, according to certain ratios of weights. The invention can be made to any type of medicament that can be accepted by the clinic or pharmacology, which is the good quality oral preparation. The medicine has effects of Qi-replenishing, Yin-nourishing and pulse-invigorating and blood circulation activating to dissipate blood stasis and lipid lowing, which can be used to curing the chest distress, hard breathe, heart-throb, angina and arrhythmia caused by coronary heart disease and miocardial infarction, the recovery period of the cerebral thrombosis and the sequelae of the cerebral thrombosis, the effects are obvious.

The invention relates to a traditional Chinese medicine, and in particular to a black fungus and gingko compound capsule with functions of lowering blood fat, preventing thrombosis, myocardial infarction and cerebral infarction, improving immunity and resisting aging. The compound capsule is characterized by being prepared from, by weight, 4.6-6.1 parts of black fungus, 7-8 parts of ginkgo, 4.5-6 parts of perilla seed, 3.5-5.0 parts of the root of kudzu vine, 4.5-6.0 parts of rhizoma polygonati and 4.5-6.0 parts of Houttuynia. A preparation method is as below: drying and crushing black fungus, sieving through a 100-mesh sieve to obtain a black fungus powder for standby; cleaning ginkgo, perilla seed, the root of kudzu vine, rhizoma polygonati and Houttuynia; adding water and decocting two times for 2 hours each time; mixing the two decoction, filtering, concentrating the filtrate into a thick paste and drying at 80 DEG C, spraying the powder through a 100-mesh sieve; and evenly mixing the black fungus powder with the Chinese herbal medicine extracted powder and filling capsules with the mixture. The invention has the advantages of simple technology, simple operation and applicability to industrialized production. The black fungus and gingko compound capsule has the functions of lowering blood fat, preventing thrombosis, myocardial infarction and cerebral infarction, improving immunity and resisting aging, reaches significant efficiency of higher than 96%, effective rate of 89% and cure rate of 83%.

The invention discloses health-care vinegar, a brewing method and application in preventing cardiovascular diseases thereof. The method comprises the following steps: (1) removing peel of 6 to 7 weight percent of fresh kudzuvine root after the fresh kudzuvine root is cleaned, adding water or medicinal extract for homogenating, and regulating the quality concentration of starch to be over 10 percent; (2) heating the homogenated fresh kudzuvine root for 10 to 20 minutes at the temperature of between 120 and 125 DEG C; (3) adding rhizopus, activated dried yeast, aroma-producing yeast and lactic acid bacteria into the sterilized mixture to ferment distilled wort, adding 10 percent lactic acid bacteria seed fermentation broth into the mixture when the alcohol content is detected to be between 6 and 8 percent, leading the fermentation temperature to be between 26 and 34 DEG C, adding edible salt into the mixture when the acidity of the fermentation broth is not changed, and stopping alcoholic fermentation; and (4) ageing the fermented acid solution for over 15 days at the temperature of between 12 and 20 DEG C, and filtering the solution to obtain the health-care vinegar. The health-care vinegar obtained by the brewing method can effectively inhibit CPK activity caused by myocardial ischemia and myocardial infarction, can reduce ET content (P is less than 0.05), has inhibition effect on LDH, can be used in preparation of medicament for preventing cardiovascular diseases, and has wide application prospect.

The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.

Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.

The invention discloses a traditional Chinese medicine preparation for treating myocardial infarction. The traditional Chinese medicine preparation is prepared from the following raw pharmaceutical materials all in parts by weight: 2-6 parts of licorice powder, 20-45 parts of Eugenia caryophyllata Thunb, 2-6 parts of saffron crocus, 20-45 parts of cattail pollen, 20-45 parts of Mongolian snakegourd, 6-15 parts of radix curcumae, 20-45 parts of barley malt, 2-6 parts of dalbergia wood, 6-15 parts of ophiopogon root and 0.05-0.5 part of borneol. According to the traditional Chinese medicine preparation, medicinal resources are easily obtained, and medicinal materials are low in cost, so that the burden on sufferers can be reduced; the selected materials are all traditional Chinese medicine materials and are free from any toxic and side effects.